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Objective: Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery
and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery.
Methods:We studied the impact of preoperative renal dysfunction (creatinine clearance<60 mL/min) on 1-year
internal thoracic artery and saphenous vein graft failure (defined as  75% angiographic stenosis) and 2-year
clinical events (death; death or myocardial infarction; and death, myocardial infarction, or revascularization)
in 3014 patients undergoing coronary artery bypass surgery enrolled in the Project of Ex-vivo Vein Graft Engi-
neering via Transfection-IV study.
Results: Of 2973 patients (98.6%) with preoperative measurement of renal function, 440 (14.8%) had renal
dysfunction. Most baseline comorbidities were higher in these patients. Two-year clinical events were higher
in patients with preoperative renal dysfunction (adjusted death, myocardial infarction, or revascularization,
hazard ratio 1.21, 95% confidence interval 0.97–1.50; adjusted death or myocardial infarction, hazard ratio
1.35, 95% confidence interval 1.05–1.74; adjusted death, hazard ratio 1.47, 95% confidence interval 0.98–
2.21). However, saphenous vein graft (odds ratio 1.02, 95% confidence interval 0.79–1.33) and internal thoracic
artery (odds ratio 0.76, 95% confidence interval 0.40–1.44) failure were similar in the 2 groups.
Conclusion:Although the risk of adverse clinical events is higher in patients with preoperative renal dysfunction,
that of internal thoracic artery and saphenous vein graft failure is not. This suggests that factors other than graft
failure account for the worse clinical outcomes in this high-risk cohort. Further studies are needed to identify other
mechanisms of these worse outcomes so that appropriate measures can be developed to improve long-term
outcomes in patients with renal dysfunction undergoing coronary artery bypass surgery.Renal insufficiency in patients undergoing coronary artery
bypass graft (CABG) surgery has been shown to be associated
with high short-term morbidity and mortality, and increased
resource use.1-4 However, the influence of preoperative renal
dysfunction on short- and long-term graft patency and its
relationship to outcomes of patients undergoing CABG at
a wide range of hospitals is less well known.
The goal of the present investigation was to evaluate the
impact of preoperative renal dysfunction on in-hospital
and 2-year clinical outcomes and 1-year angiographic out-
comes in patients undergoing CABG using data from the
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function before CABG would be associated with increased
short-term morbidity and mortality and that this elevated
risk would persist beyond the acute phase and be observed
at the 2-year follow-up. In addition, we theorized that these
worse outcomes were, at least in part, mediated through
higher rates of graft failure in this high-risk group.
MATERIALS AND METHODS
PREVENT-IV Trial and Patient Population
The details of PREVENT-IV trial have been published.5,6 In brief, PRE-
VENT-IV was a phase 3, multicenter, randomized, double-blind, placebo-
controlled trial to assess the efficacy of edifoligide an oligonucleotide decoy
that binds to and inhibits E2F transcription factors and is thereby thought to
prevent neointimal hyperplasia and vein graft failure. A total of 3014 pa-
tients undergoing primary CABG surgery with at least 2 planned vein grafts
at 107 sites in the United States were randomly assigned between August of
2002 and October of 2003 to ex vivo autologous vein graft treatment with
either edifoligide or placebo before implantation of these conduits. The first
2400 patients enrolled were assigned to an angiographic cohort and sched-
uled to return for angiography 12 to 18 months after surgery. Major exclu-
sion criteria included previous cardiac surgery or planned concomitant valve
surgery (because of the increased early mortality associated with these pro-
cedures), vasculitis or another nonatherosclerotic cause of coronary artery
disease, hypercoagulable state, involvement in another investigational
drug or device study within 30 days, or a comorbid illness that wouldrdiovascular Surgery c Volume 136, Number 5 1149
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DAbbreviations and Acronyms
CABG ¼ coronary artery bypass graft
CK ¼ creatine kinase
ITA ¼ internal thoracic artery
MI ¼ myocardial infarction
PREVENT-IV ¼ PRoject of Ex-vivo Vein Graft
Engineering via Transfection-IV
SVG ¼ saphenous vein graft
ULN ¼ upper limit of normal
make 5-year survival unlikely. Institutional review board approval was ob-
tained at all sites, and all patients gave written informed consent before par-
ticipation. For the purpose of this analysis, we included all patients enrolled
in the PREVENT-IV study. Creatinine clearance was determined as
[(140age) * weight)/(72 * creatinine)] * 0.85 if the patient was female.7
Preoperative renal dysfunction was defined as creatinine clearance less
than 60 mL/min.
Outcome Measures
The main angiographic outcome measure for this analysis was vein graft
failure, defined as a stenosis of 75% or greater in at least 1 vein graft assessed
by quantitative coronary angiography 12 to 18 months after surgery in pa-
tients who underwent follow-up angiography. Patients in the angiographic co-
hort who underwent angiography for clinical reasons before 12 months and
met the above end point did not have additional protocol angiography. Pa-
tients who died before angiography were not included in the angiographic
end point. Secondary angiographic end points included (1) per graft incidence
of vein graft failure (75% stenosis and vein graft occlusion) and (2) per graft
incidence of vein graft occlusion. All angiograms in PREVENT-IV were in-
terpreted at the PERFUSEAngiographic Core Laboratory (Boston,Mass), us-
ing standard quantitative coronary angiographic techniques. Themain clinical
end point for this analysis is the composite of death, myocardial infarction
(MI), or repeat revascularization at 2 years.
In PREVENT-IV trial, patients were contacted via mail or telephone at 6
and 9 months and at 1 year after CABG surgery. Annual follow-up is ongo-
ing and planned at 2, 3, 4, and 5 years after CABG surgery. Two-year fol-
low-up is complete at this time. For those who reported a possible MI or
revascularization procedure, additional medical records were obtained
from their hospitals. All suspected MIs and revascularization procedures
were adjudicated by a blinded, independent clinical events committee using
prespecified criteria. Perioperative MI was defined as a creatine kinase-MB
(CK-MB) fraction of greater than 10 times the upper limit of normal (ULN)
or greater than 5 times the ULN with new Q waves longer than 30 ms in 2
contiguous leads or, if postoperative CK-MB samples were not available,
new Q waves longer than 30 ms in 2 contiguous leads. Perioperative MI
was diagnosed if CK-MB was elevated within 24 hours of surgery when
there was not an interval clinical event and when the elevation was not at-
tributable to a preoperativeMI. PostoperativeMIwas defined as either spon-
taneous (CK-MB> 2 times the ULN or new Q waves> 30 ms in 2
contiguous leads), after percutaneous coronary intervention (CK-MB> 3
times the ULN or new Q waves> 30 ms in 2 contiguous leads), or after
CABG surgery (CK-MB>10 times the ULN or>5 times the ULN with
new Q waves>30 ms in 2 contiguous leads). For patients for whom CK-
MB samples and electrocardiograms were not available, MI could be de-
fined by the presence of ‘‘myocardial infarction,’’ ‘‘heart attack,’’ or similar
term in the medical record documenting that an MI had occurred after the
initial CABG procedure. Postprocedure acute renal dysfunction was defined
as an increase of 50% or more and/or 0.7 mg/dL or more in preprocedure
serum creatinine or serum creatinine more than 2.0 mg% or requirement
for dialysis after the CABG.1150 The Journal of Thoracic and Cardiovascular SStatistical Analysis
All analyses were performed with SAS software (SAS Inc, Cary, NC).
Baseline characteristics, surgery, and hospital care characteristics were sum-
marized in terms of frequencies and percentages for categoric variables and
by the median, 25th, and 75th percentiles for continuous variables. Differ-
ences in characteristics between patients with and without preoperative re-
nal dysfunction were assessed using the Wilcoxon rank-sum test (for
continuous variables) and the chi-square or Fisher’s exact test (for categoric
variables). All tests of significance were 2-tailed.
Cumulative event rates for the main adverse coronary event outcomes
were calculated by the Kaplan–Meier method. The statistical significance
of differences in outcomes between the 2 groups was assessed with the
log-rank test. In addition, covariate adjusted analyses of outcomes were as-
sessed using the Cox proportional hazards model. Covariates adjusted for
included age, gender, history of congestive heart failure, recent MI (within
30 days before enrollment), and use of an internal thoracic artery (ITA) con-
duit. Hazard ratios and 95% confidence intervals were calculated with the
Cox model.
For the per graft end points of 75% or greater stenosis and occlusion,
general estimating equation techniques were used to adjust for correlation
between grafts within a patient. Covariates adjusted for included weight, du-
ration of surgery, harvest technique, target artery quality, and whether it was
a composite graft.
RESULTS
Baseline Characteristics, Surgical Features, and
In-hospital Care
Of 2973 patients (98.6% of the PREVENT-IV popula-
tion) with preoperative measurement of renal function, 440
(14.8%) had preoperative moderate (creatinine clearance
30 to<60 mL/min, 419 [14.1%]) or severe (creatinine clear-
ance<30 mL/min, 21 [0.7%]) renal dysfunction (Tables 1
and 2). Mild renal dysfunction (creatinine clearance 60 to
<90) was present in more than one third of patients (n ¼
1115 [37.5%]). No patient on dialysis before CABG was
enrolled in the PREVENT-IV study. Table 1 shows the base-
line characteristics of the 2 groups. The median age of
patients with preoperative renal dysfunction was 11 years
older than patients without renal dysfunction. These patients
were more likely to be women and non-white. Similarly, the
median weight was 17 kg lower and height was 7 cm shorter
in patients with preoperative renal dysfunction than those
without preoperative renal dysfunction. Most comorbid con-
ditions, including hypertension, chronic lung disease, prior
congestive heart failure, prior stroke, and prior peripheral
and cerebrovascular disease, were higher in patients with
preoperative renal dysfunction than in those without preop-
erative renal dysfunction. These patients had higher systolic
and lower diastolic blood pressure. No differences were
noted in the prevalence of diabetes, hyperlipidemia, prior
MI, New York Heart Association class, and number of dis-
eased vessels or left ventricular ejection fraction.
The median number of saphenous vein grafts (SVGs) per
patient did not differ between the 2 groups. In contrast, the
proportion of patients receiving an ITA graft was lower for
the preoperative renal dysfunction group. In addition, the
quality of target vessels (graded as good, fair, and poor)urgery c November 2008
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Characteristics Overall No renal dysfunction Preoperative renal dysfunction P value
N 2973 2533 440
Age, median (IQR), y 64 (56–71) 62 (55–68) 73 (68–76) <.001
Female sex 20.9% 17.4% 40.7% <.001
Race nonwhite 8.9% 8.5% 11.1% .028
Weight (median [IQR]), kg 88 (77–100) 90 (79–102) 73 (64–83) <.001
Height (median [IQR]), cm 175 (168–180) 175 (168–180) 168 (160–175) <.001
Medical history
Hypertension 75.0% 73.8% 81.6% .001
Diabetes mellitus 37.6% 37.7% 37.0% .781
Current smoking 22.7% 24.1% 15.0% <.001
Hyperlipidemia 76.2% 76.6% 74.3% .304
Chronic lung disease 15.6% 14.9% 19.8% .010
Preoperative atrial 7.1% 6.4% 10.7% .001
Fibrillation/flutter
MI, any 42.1% 41.8% 43.9% .411
MI within 3 mo 21.7% 21.8% 21.1% .772
Prior percutaneous coronary interventions 25.8% 26.1% 23.9% <.001
Congestive heart failure 9.4% 8.2% 16.1% <.001
Prior stroke 5.4% 4.6% 10.2% <.001
Peripheral vascular disease 12.3% 11.0% 20.0% <.001
Cerebrovascular disease 12.6% 10.8% 23.2% <.001
History of liver disease 1.8% 1.7% 2.0% .652
Cardiogenic shock 0.8% 0.8% 1.1% .386
Presenting features
Presenting heart rate (median [IQR]), beats/min 70 (62–80) 70 (62–80) 70 (60–80) .285
Presenting SBP (median [IQR]), mm Hg 134 (120–149) 133 (120–148) 137 (123–154) <.001
Presenting DBP (median [IQR]), mm Hg 75 (67–82) 75 (68–82) 73 (64–80) .002
Peoperative NYHA class .374
I 40.2% 40.7% 37.3%
II 33.4% 33.3% 33.8%
III 18.0% 17.9% 18.8%
IV 8.4% 8.1% 10.2%
Left ventricular ejection fraction, median (IQR) 50% (40%–60%) 50% (40%–60%) 55% (45%–60%) .239
No. of diseased vessels  2 or left main (>50% stenosis) 79.4% 79.3% 80.2% .785
Baseline creatinine median (IQR), mg/dL 1.0 (0.9–1.2) 1.0 (0.9–1.1) 1.4 (1.1–1.6) <.001
Creatinine clearance, median (IQR), mL/min 94 (78–117) 51 (43–56) 88 (70–112) <.001
IQR, Interquartile range; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure, NYHA, New York Heart Association.was similar in the 2 cohorts. Although there were no differ-
ences in the 2 groups in the duration of surgery or cardiopul-
monary bypass, postoperative duration on ventilator and
length of stay in the intensive care unit and hospital were sig-
nificantly longer in the preoperative renal failure group. Al-
though the overall use of some medications (particularly
aspirin, beta-blockers, and statins) was lower in the preoper-
ative renal dysfunction group, this did not differ between the
2 groups among eligible patients without contraindications
(data not shown).
Angiographic Results
In the overall PREVENT-IV population, the proportions
of patients assigned to the angiographic cohort were similar
among patients with and without renal dysfunction (n¼ 350
[80%] and 2020 [80%], respectively) (Table 3). Within theThe Journal of Thoracic and Cacohort that was scheduled to return for angiographic follow-
up, however, the proportion that actually returned for angi-
ography was lower among patients with renal dysfunction
than patients without renal dysfunction (62% vs 79%).
The number of patients who died before 18 months without
an angiogram was higher among patients with renal dys-
function than patients without renal dysfunction (70% vs
82%).
One-year follow-up angiography revealed no differences
in the adjusted rates of SVG or ITA failure (defined as steno-
sis  75%) or occlusion between the 2 groups (Figure 1).
There was also no interaction between treatment assignment
and renal dysfunction on vein graft failure in multivariate
analysis. Similarly, when the analysis was performed focus-
ing on per patient end points, the proportion of patients with
failure or occlusion of 1 or more SVGs or ITA stenosis ofrdiovascular Surgery c Volume 136, Number 5 1151
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Characteristics Overall No renal dysfunction Preoperative renal dysfunction P value
N 2973 2533 440
Urgent/emergency/emergency salvage surgery 51.4% 52.3% 46.4% .136
ITA graft 92.5% 93.2% 88.2% <.001
Surgery duration, median (IQR), min 231 (193–272) 231 (193–272) 230 (193–270) .578
Cardiopulmonary bypass 78.9% 79% 78% .608
Duration of cardiopulmonary bypass, median (IQR), min 100 (79–122) 100 (79–123) 97 (80–122) .744
Postoperative duration, median (IQR)
Ventilator, h 7.5 (4.5–13.5) 7.0 (4.5–13.0) 9.0 (5.5–16.0) <.001
Intensive care unit stay, h 26 (22–47) 25.0 (22.0–46.0) 29.0 (23.0–65.0) <.001
Hospital stay, d 6.0 (5.0–8.0) 6.0 (5.0–8.0) 7.0 (6.0–9.0) <.001
No. of treatment eligible vein grafts 2.0 (2.0–3.0) 2.0 (2.0–3.0) 2.0 (2.0–3.0) .389
Worst target artery quality .817
Good 43.0% 43.2% 41.9%
Fair 35.9% 35.8% 36.0%
Poor 21.1% 20.9% 22.1%
Medications continued at 30 d
Aspirin 90.5% 91.0% 88.0% .055
Thienopyridine 21.8% 21.6% 23.0% .507
ACE inhibitor 35.8% 36.3% 32.6% .140
Angiotensin II receptor blocker 6.8% 6.3% 9.4% .018
Beta-blockers 78.8% 79.5% 74.9% .031
HMG-CoA reductase inhibitor 72.8% 73.4% 69.2% .067
ITA, Internal thoracic artery; IQR, interquartile range; ACE, angiotensin-converting enzyme.75% or more or with complete SVG or ITA occlusion did
not differ between the 2 groups (data not shown). In addi-
tion, even when we assumed that all patients who died had
vein graft failure, there was no difference in vein graft failure
between the 2 groups (odds ratio 1.20, 95% confidence in-
terval 0.92–1.57, P ¼ .18). Finally, because the patency of
grafts would depend on the quality of the vessel on which
they are anastomosed to, we performed a sensitivity analysis
restricting our angiographic end points only to SVG and ITA
attached to a good target vessel. This analysis also failed to
reveal any difference in the rate of SVG or ITA failure or oc-
clusion between the 2 groups.1152 The Journal of Thoracic and Cardiovascular SuClinical Events
Of the clinical events evaluated in the PREVENT-IV
study through 30 days, many were more frequent in patients
with than in those without preoperative renal dysfunction
(Table 4). Most notably, the incidence of pneumonia was
1.8-fold higher, mortality was 3-fold higher, acute renal fail-
ure was 3.5-fold higher, and the need for postoperative dial-
ysis was 4-fold higher in patients with preoperative renal
dysfunction.
Two-year major adverse cardiac events are shown in
Table 5 (Figure 2). The incidence of the combined end point
of death or MI was significantly higher in patients withTABLE 3. Angiographic results
Preoperative renal dysfunction Unadjusted Adjusted*
Per graft angiographic end points Yes (n ¼ 508) No (n ¼ 3735) Odds ratio (95% CI) P Odds ratio (95% CI) P
SVG stenosis  75% 26.6% 25.1% 1.08 (0.63–1.38) .5569 1.02 (0.79–1.33) .8673
SVG occlusion 24.0% 22.0% 1.10 (0.85–1.43) .4472 1.04 (0.79–1.36) .7816
Grafts with ‘‘good’’ target arteries (n ¼ 333) (n ¼ 2377)
SVG stenosis  75% 20.4% 22.3% 0.92 (0.67–1.26) .5965 0.81 (0.58–1.13) .2109
SVG occlusion 18.0% 19.7% 0.92 (0.66–1.28) .6327 0.80 (0.56–1.13) .2001
ITA graft-Total (n ¼ 172) (n ¼ 1405)
ITA stenosis  75% 6.4% 8.3% 0.76 (0.40–1.44) .3974 - -
ITA occlusion 1.7% 3.9% 0.45 (0.14–1.47) .1863 - -
ITA with ‘‘good’’ target arteries (n ¼ 122) (n ¼ 940)
ITA stenosis  75% 7.4% 8.6% 0.84 (0.41,1.71) .6256 - -
ITA occlusion 2.5% 4.0% 0.60 (0.18,1.97) .3983 - -
CI, Confidence interval; SVG, saphenous vein graft; ITA, internal thoracic artery. *Adjusted for weight, duration of surgery, harvest technique, target vessel quality, and composite
grafts.rgery c November 2008
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Dpreoperative renal dysfunction. After adjustment for differ-
ences in prognostically important baseline variables and dif-
ferences in ITA use, the preoperative renal dysfunction
cohort continued to demonstrate a significant 34% increased
risk of death or MI at 2 years follow-up. Similar trends were
noted for increased risks of the composite of death, MI, or
revascularization and for death at 2 years with 19% and
47% higher risks of these events, respectively, in the preop-
erative renal dysfunction group.
DISCUSSION
Patients with varying degree of renal dysfunction consti-
tute an increasing proportion of those undergoing CABG.1-4
This escalating trend is the result of the increased risk of car-
diovascular disease in patients with even mild renal dysfunc-
tion8,9 attributed to the high prevalence of risk factors, such
as hypertension, diabetes, smoking, dyslipidemia, peripheral
vascular disease, and advanced age.1,10 Multiple studies
have confirmed that CABG is associated with increased
risk of mortality and morbidity in this high-risk cohort.1-4
However, the alternative strategies for the management of
One-year Graft Failure
1.02
1.08
0.45
0.76
1.04
1.10
0 0.5 1 1.5 2
Odds Ratio (95% CI)
Unadj SVG Stenosis >75%
Adj SVG Stenosis >75%
Unadj SVG Occlussion
Adj SVG Occlussion
Unadj IMA Stenosis >75%
Unadj IMA Occlussion
FIGURE 1. Unadjusted and adjusted clinical events in patients with preop-
erative renal dysfunction compared with those with no preoperative renal
dysfunction.The Journal of Thoracic and Cathese patients have been even more disappointing. Conser-
vative medical treatment has been shown to have dismal out-
comes,11,12 whereas percutaneous coronary interventions,
despite high procedural success rates, have been shown to
be associated with increased incidence of restenosis needing
repeat revascularization and high short- and long-term
morbidity and mortality.2,3,11-14 Although there is no ran-
domized clinical trial that has evaluated the optimal revascu-
larization strategy in patients with renal dysfunction,
multiple observational studies have consistently shown
that overall outcomes are better with CABG than with percu-
taneous coronary interventions.2,3,12,13,15,16
Our study adds to the growing evidence that patients with
preoperative renal dysfunction in patients undergoing
CABG represent a distinct group with increased comorbid
conditions and are at higher risk of both short- and 2-year
clinical adverse events. Death, pneumonia, acute renal
failure, and need for dialysis featured prominently among
the short-term risks associated with preoperative renal
dysfunction, whereas the composite of death or MI were
significantly increased at 2 years among patients with preop-
erative renal dysfunction than in those without preoperative
renal dysfunction.
A number of mechanisms have been proposed to explain
the propensity for worse clinical outcomes in patients with
preoperative renal dysfunction.17 These factors include
greater comorbid conditions, lower use of evidence-based
therapies (aspirin, beta-blockers, angiotensin-converting en-
zyme inhibitors or angiotensin receptor blockers, and sta-
tins), greater incidence of complications, and accelerated
atherosclerosis. Our findings provide important insights
into understanding the contributions of these factors in the
attendant risks of patients with renal dysfunction undergoing
CABG. Our data suggest that some, but not all, of these fac-
tors are operative in the heightened risks of these patients.
Clearly, the increased comorbid conditions associated with
preoperative renal dysfunction account considerably for
their worse outcomes after CABG, as suggested byTABLE 4. Clinical events through 30 days
Clinical events
Overall
(n ¼ 2973)
No renal dysfunction
(n ¼ 2533)
Preoperative renal dysfunction
(n ¼ 330) P value
Death 1.2% (35) 0.9% (23) 2.7% (12) .0011
Atrial fibrillation 26.0% (774) 25.3% (640) 30.5% (134) .0221
Bleeding requiring reoperation 2.5% (74) 2.3% (58) 3.6% (16) .0942
Pneumonia 2.3% (69) 2.1% (52) 3.9% (17) .0199
Stroke 1.6% (46) 1.4% (35) 2.5% (11) .0794
Adult respiratory distress syndrome 0.9% (25) 0.8% (20) 1.1% (5) .4622
Mediastinitis 0.7% (21) 0.8% (20) 0.2% (1) .1936
Pulmonary embolism 0.6% (17) 0.6% (16) 0.2% (1) .2991
Perioperative MI 9.8% (291) 9.6% (243) 10.9% (440) .3913
Postoperative acute renal failure 3.3% (98) 2.4% (60) 8.6% (38) <.0001
Postoperative dialysis 0.6% (17) 0.4% (10) 1.6% (7) .0021
MI, Myocardial infarction.rdiovascular Surgery c Volume 136, Number 5 1153
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Preoperative renal dysfunction Unadjusted Adjusted*
Clinical events No (n ¼ 2533) Yes (n ¼ 440) Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Death, MI (including perioperative MI), or
revascularization
No. of events 569 121 1.26 .0193 1.19 .1240
2-y event rate 22.6% 27.6% (1.04–1.54) (0.97–1.50)
Death or MI (including perioperative MI)
No. of events 350 98 1.65 <.0001 1.3 .0249
2-y event rate 13.8% 22.3% (1.32–2.06) (1.04–1.72)
Death or revascularization
No. of events 360 78 1.30 .0381 1.18 .2253
2-y event rate 14.3% 17.8% (1.01–1.66) (0.90–1.55)
Death
No. of events 93 44 2.83 <.0001 1.47 .0653
2-y event rate 3.7% 10.0% (1.98–4.05) (0.98–2.21)
CI, Confidence interval; MI, myocardial infarction, *adjusted for age, gender, congestive heart failure, MI within 30 days of enrollment and use of ITA conduit.significant attenuation of the risk of the outcomes on multi-
variable adjustments for these confounders. The increased
postoperative morbidities (pneumonia, atrial fibrillation,
postoperative acute renal failure, and need for dialysis, and
the trend for increased incidence of postoperative bleeding
and stroke) also seem to play an important role.
The use of evidence-based therapies did not differ signifi-
cantly in patients with and without renal dysfunction under-
going CABG in our study. This is probably because the
PREVENT-IV population may represent a highly select
group already subjected to the most invasive coronary revas-
cularization strategy (ie, CABG). Perhaps physicians are
more concerned with preventing recurrent events in this co-
hort and less worried about the risks antecedent to the use
of any evidence-based therapies. One notable exception
was the lower use of ITA in patients with postoperative renal
dysfunction. The use of ITA conduit in patients undergoing
CABG has been shown to be associated with better short-
and long-term outcomes18 and is now considered a marker
Two-year Major Adverse Clinical Events (MACE)
2.83
1.34
1.65
1.19
1.26
1.47
0 1 2 3 4 5
Hazard Ratio (95% CI)
Unadj Death/MI/Revasc
Adj Death/MI/Revasc
Unadj Death/MI
Adj Death/MI
Unadj Death
Adj Death
FIGURE 2. Unadjusted and adjusted graft failure rates in patients with pre-
operative renal dysfunction compared with those with no preoperative renal
dysfunction. Small number of events precluded adjustments for ITA groups.1154 The Journal of Thoracic and Cardiovascular Sof quality of care provided by health care institutions for pa-
tients undergoing CABG.19 Certainly this factor potentially
influenced the short- and 2-year adverse clinical events
among patients in our study as suggested by some attenuation
of the risk of these events on risk adjustment. Nonetheless,
this did not account completely for all of the increased risk
of adverse clinical events in the current cohort, and preoper-
ative renal dysfunction remained an important independent
correlate of these events at follow-up. This and other previous
investigations1-3 suggest that differences in evidence-based
therapies seem to have small yet definite effects on the differ-
ential risks of patients with and without preoperative renal
dysfunction undergoing CABG. Thus, improving evidence-
based care and increasing the use of ITA conduits in patients
with preoperative renal dysfunction undergoing CABG rep-
resent important strategies for improving their outcomes.
Most important, we found no difference in incidence of
SVG or ITA failure and repeat revascularization in the 2 co-
horts, a finding not demonstrated in any previous study. Fur-
thermore, in those with similar quality of coronary arteries to
which the grafts were anastomosed (categorized as good,
fair, and poor), the failure rates of grafts did not differ.
Thus, on the basis of our data, SVG or ITA failure or repeat
revascularization of these conduits (markers of accelerated
atherosclerosis) seemed to be similar among all patients un-
dergoing CABG and less influenced by preoperative renal
dysfunction. Thus, SVG and ITA failure is less likely to
have a significant influence on the increased morbidity and
mortality seen among patients with preoperative renal dys-
function undergoing CABG. Finally, treatment assignment
(edifoligide vs placebo) had no differential effect on vein
graft failure in patients with and without renal dysfunction.
Strength and Limitations
Our investigation should be viewed in the light of its
strength and limitations. This is the first study tourgery c November 2008
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data that allowed assessment of SVG or ITA graft failure and
repeat revascularization. This clinical and angiographic data
permitted important insight into the mechanisms underlying
the worse outcomes observed in patients with preoperative
renal dysfunction undergoing CABG. However, this is a ret-
rospective observational analysis of the PREVENT-IV data
and limits inference regarding causation. Nonetheless,
a large observational study such as this can be informative
and hypothesis generating. Patients on dialysis were not ex-
cluded. However, patients with moderate to severe renal
dysfunction may have been excluded from the PREVENT-
IV study because of the need for angiographic follow-up.
In addition, in the angiographic cohort, fewer patients with
renal dysfunction underwent scheduled angiography. This
was partly because patients with renal dysfunction were
more likely to die before angiography. Unfortunately, we
are unable to determine the rates of graft failure among pa-
tients who did not have follow-up angiography, potentially
biasing our results. When we assumed that all deaths were
associated with vein graft failure, however, we still found
no significant in vein graft failure between patients with
and without renal dysfunction. Follow-up beyond 2 years
may provide additional information, and efforts are ongoing
to collect this information. Finally, our findings are applica-
ble to patients undergoing CABG and have limited general-
izability to other patients with cardiovascular disease and
renal dysfunction.
CONCLUSIONS
We found that patients with preoperative renal dysfunc-
tion have an increased risk of adverse short-term and 2-
year clinical events after CABG. These data provide further
insight into the factors influencing the risk of worse out-
comes that include worse comorbidities, more post-CABG
complications, and lower use of ITA with relative lesser im-
pact of SVG or ITA failure. Further studies are needed to
identify additional mechanisms of these worse outcomes
and to evaluate appropriate measures that can improve the
outcomes of patients with preoperative renal dysfunction
undergoing CABG.The Journal of Thoracic and CReferences
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